Satsuma Pharmaceuticals Inc (STSA)


Stock Price Forecast

June 8, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Satsuma Pharmaceuticals Inc chart...

About the Company

satsuma pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.

CEO

John Kollins

Exchange

NASDAQ

Website

satsumarx.com

$17M

Total Revenue

25

Employees

$36M

Market Capitalization

-1.86

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $STSA News

Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session

11mon ago, source: Hosted on MSN

Marpai, Inc. (NASDAQ: MRAI ... get started now. This article Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session originally ...

After Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upside

11mon ago, source: Hosted on MSN

C linical-stage migraine and neurological disorder focused biopharma Satsuma Pharmaceuticals Inc surged 64% in trading on Monday after Shin Nippon Biomedical Laboratories announced a takeover ...

Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?

11mon ago, source: Hosted on MSN

Satsuma Pharmaceuticals (NASDAQ:STSA) stock is taking off on Monday after revealing an acquisition deal with Shin Nippon Biomedical Laboratories. That deal has Shin Nippon Biomedical Laboratories ...

Satsuma Pharmaceuticals GAAP EPS of -$0.70

11mon ago, source: Hosted on MSN

Satsuma Pharmaceuticals press release (NASDAQ:STSA): Q4 GAAP EPS of -$0.70. Impairment loss was $11.7 million for the fourth quarter and full year 2022 Research and development expenses were $8.7 ...

Japan’s Shin Nippon Biomedical Labs to buy US-based Satsuma for nasal powder migraine drug

11mon ago, source: Hosted on MSN

Japan's Shin Nippon Biomedical Labs (SNBL) agreed to buy US-based Satsuma Pharmaceuticals and the rights to the STS101 nasal powder migraine medicine, in a deal that values the Nasdaq-listed ...

Combination drug-device

2mon ago, source: BioWorld

The U.S. FDA issued a complete response letter to Shin Nippon Biomedical Laboratories Ltd.’s U.S. subsidiary, Satsuma Pharmaceuticals Inc., for its NDA for dihydroergotamine nasal powder (STS-101) for ...

TPG Group Holdings (SBS) Advisors, Inc.'s Net Worth

1mon ago, source: Benzinga.com

Who is TPG Group Holdings (SBS) Advisors, Inc.? TPG Group Holdings (SBS) Advisors, Inc. has an estimated net worth of $36.8 Billion. This is based on reported shares across multiple companies ...

Vertex Pharmaceuticals Inc VRTX

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Amylyx Pharmaceuticals Inc AMLX

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

STSA_old Historical Data

1mon ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...